{
  "claim_id": "claim_004",
  "claim": "Vaccination with a higher-dose recombinant flu vaccine may induce a more robust antibody response than egg-based standard-dose vaccines.",
  "document": "Liu_et_al.__2024_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 3,
    "new_evidence_found": 3,
    "total_evidence": 5
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "In year 1, RIV4 induced higher neutralizing and total HA head binding antibodies to cell- A (H3 N2) virus than ccIIV4 and IIV4.",
      "relevance_explanation": "This quote directly compares the antibody response induced by the higher-dose recombinant vaccine (RIV4) to that of standard-dose egg-based vaccines (IIV4), showing that RIV4 produced higher neutralizing and binding antibodies against the A (H3 N2) virus, supporting the claim."
    },
    {
      "id": 2,
      "quote": "RIV4 contains 3 times the intended 45 \u00b5g HA/dose/strain compared to IIV4 and ccIIV4 (15 \u00b5g HA/dose/strain). For A (H3 N2), RIV4 vaccination not only improved the quality of the functional neutralizing antibody response in both age groups, it also significantly increased the quantity of the total A (H3 N2) cell HA head binding antibodies (Fig. 4 A, Fig. S1 A).",
      "relevance_explanation": "This quote specifies that RIV4 is a higher-dose recombinant vaccine and provides evidence that it leads to a greater quantity of antibody response compared to standard-dose vaccines, directly supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "In year 2, among the 7 repeat vaccination arms (IIV4-IIV4, IIV4-ccIIV4, IIV4-RIV4, RIV4-ccIIV4, RIV4-RIV4, ccIIV4-ccIIV4 and ccIIV4-RIV4), repeat vaccination with either RIV4 or ccIIV4 further improved antibody responses to circulating viruses.",
      "relevance_explanation": "This quote shows that repeat vaccination with the recombinant (higher-dose) RIV4 vaccine led to improved antibody responses compared to standard egg-based vaccines, supporting the claim of a more robust antibody response.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "The RIV4 group had the highest A (H1 N1) pdm09 HA stalk and A (H3 N2) HA stalk antibodies at 1 month post vaccination, however the fold rises of HA stalk antibodies were low (<1.8) and similar among all 4 vaccine groups (Fig. 4 D).",
      "relevance_explanation": "This quote indicates that the RIV4 (higher-dose recombinant) group achieved the highest levels of certain antibodies post-vaccination, supporting the claim that it may induce a more robust antibody response than standard egg-based vaccines.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "Comparing pre- and 1 month post vaccination, A (H3 N2) HA stalk binding antibodies were significantly boosted in ccIIV4-RIV4, RIV4-RIV4, IIV4-ccIIV4, and IIV4-RIV4 arms, while A (H1 N1) pdm09 HA stalk binding antibodies were also significantly boosted in ccIIV4-ccIIV4 and RIV4-ccIIV4 arms (Fig. 8 C).",
      "relevance_explanation": "This quote demonstrates that vaccination regimens including RIV4 (the higher-dose recombinant vaccine) significantly boosted antibody responses, supporting the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}